当前位置: 首页 >> 检索结果
141. 18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value.
作者: Chantal A M Bouman.;Noortje van Herwaarden.;Annelies B Blanken.;Conny J Van der Laken.;Martin Gotthardt.;Wim J G Oyen.;Alfons A den Broeder.;Aatke van der Maas.;Cornelia H van den Ende.
来源: Rheumatology (Oxford). 2022年61卷SI期SI6-SI13页
To investigate the reliability and validity of fluorine-18 fluorodeoxyglucose (18F-FDG) PET-CT scanning (FDG-PET) in RA patients with low disease activity tapering TNF inhibitors (TNFis) and its predictive value for successful tapering or discontinuation.
142. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
作者: Frank Behrens.;Philipp Sewerin.;Eugenio de Miguel.;Yusuf Patel.;Anastas Batalov.;Eva Dokoupilova.;Christine Kleinmond.;Effie Pournara.;Ankita Shekhawat.;Claudia Jentzsch.;Annette Wiedon.;Xenofon Baraliakos.; .
来源: Rheumatology (Oxford). 2022年61卷7期2856-2866页
ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles' tendon enthesitis in spondyloarthritis (SpA) patients.
143. A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis.
作者: Melody P Chung.;Antonia Valenzuela.;Shufeng Li.;Benjamin Catanese.;Kate Stevens.;David Fiorentino.;Vibeke Strand.;Lorinda Chung.
来源: Rheumatology (Oxford). 2022年61卷6期2441-2449页
We evaluated the safety and efficacy of oral treprostinil in preventing progression of SSc-associated calcinosis.
144. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
作者: John H Stone.;Helen Spotswood.;Sebastian H Unizony.;Martin Aringer.;Daniel Blockmans.;Elisabeth Brouwer.;Maria C Cid.;Bhaskar Dasgupta.;Juergen Rech.;Carlo Salvarani.;Robert Spiera.;Min Bao.
来源: Rheumatology (Oxford). 2022年61卷7期2915-2922页
Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated.
145. Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians.
作者: Melanie Sloan.;Elliott Lever.;Rupert Harwood.;Caroline Gordon.;Chris Wincup.;Moira Blane.;James Brimicombe.;Peter Lanyon.;Paul Howard.;Stephen Sutton.;David D'Cruz.;Felix Naughton.
来源: Rheumatology (Oxford). 2022年61卷6期2262-2274页
The Covid-19 pandemic necessitated a rapid global transition towards telemedicine; yet much remains unknown about telemedicine's acceptability and safety in rheumatology. To help address this gap and inform practice, this study investigated rheumatology patient and clinician experiences and views of telemedicine.
147. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
作者: Samuel K Shinjo.;Fernando H C de Souza.;Isabela B P Borges.;Alexandre M Dos Santos.;Renata Miossi.;Rafael G Misse.;Ana C Medeiros-Ribeiro.;Carla G S Saad.;Emily F N Yuki.;Sandra G Pasoto.;Léonard V K Kupa.;Carina Ceneviva.;Júlia C Seraphim.;Tatiana N Pedrosa.;Margarete B G Vendramini.;Clóvis A Silva.;Nádia E Aikawa.;Eloisa Bonfá.
来源: Rheumatology (Oxford). 2022年61卷8期3351-3361页
To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities and therapy on immune response.
148. Effect of preformed foot orthoses in reducing pain in children with juvenile idiopathic arthritis: a multicentre randomized clinical trial.
作者: Antoni Fellas.;Davinder Singh-Grewal.;Jeffrey Chaitow.;Derek Santos.;Matthew Clapham.;Andrea Coda.
来源: Rheumatology (Oxford). 2022年61卷6期2572-2582页
The aim of this study is to investigate the effect of customized preformed foot orthoses on pain, quality of life, swollen and tender lower joints and foot and ankle disability in children with JIA.
149. Tapentadol effects on brain response to pain in sensitized patients with knee osteoarthritis.
作者: Jesus Pujol.;Gerard Martínez-Vilavella.;Andrea Doreste.;Laura Blanco-Hinojo.;Fabiola Ojeda.;Jone Llorente-Onaindia.;Luciano Polino.;Joan Deus.;Jordi Monfort.
来源: Rheumatology (Oxford). 2022年61卷6期2335-2345页
Pain sensitization, in the form of knee tenderness and anatomically spread hyperalgesia, is notably common in patients with knee OA and is often refractory to conventional interventions. Tapentadol, as an opioid receptor agonist and noradrenaline reuptake inhibitor, has been proposed as a potentially effective symptomatic treatment for pain-sensitized OA patients. We empirically tested whether tapentadol could attenuate brain response to painful stimulation on the tender knee using functional MRI.
150. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
作者: Sunao Kojima.;Kazuaki Uchiyama.;Naoto Yokota.;Eiichi Tokutake.;Yutaka Wakasa.;Shinya Hiramitsu.;Masako Waki.;Hideaki Jinnouchi.;Hirokazu Kakuda.;Takahiro Hayashi.;Naoki Kawai.;Masahiro Sugawara.;Hisao Mori.;Kenichi Tsujita.;Kunihiko Matsui.;Ichiro Hisatome.;Yusuke Ohya.;Kazuo Kimura.;Yoshihiko Saito.;Hisao Ogawa.; .
来源: Rheumatology (Oxford). 2022年61卷6期2346-2359页
Hyperuricaemia is recognized as an independent risk marker for cardiovascular and renal diseases. However, uric acid is a powerful free-radical scavenger, and the optimal level of serum uric acid (SUA) determining outcomes is unknown. This study explored whether interventional treatments for excessive SUA reduction were harmful and what constituted the optimal lowering of SUA levels for the prevention of events in patients with asymptomatic hyperuricaemia.
151. Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial.
作者: Jerold Jeyaratnam.;Anna Simon.;Inmaculada Calvo.;Tamas Constantin.;Anna Shcherbina.;Michael Hofer.;Marco Gattorno.;Alberto Martini.;Brigitte Bader-Meunier.;Bas Vastert.;Jeremy Levy.;Elise Dekker.;Fabrizio de Benedetti.;Joost Frenkel.
来源: Rheumatology (Oxford). 2022年61卷5期2088-2094页
To evaluate the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency during the open label extension (weeks 41-113) of the randomized controlled CLUSTER trial.
152. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
作者: Yen Lin Chia.;Jianchun Zhang.;Raj Tummala.;Tomas Rouse.;Richard A Furie.;Eric F Morand.
来源: Rheumatology (Oxford). 2022年61卷5期1900-1910页
To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from two phase 3 trials.
153. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.
作者: Maria Antonietta D'Agostino.;Georg Schett.;Alejandra López-Rdz.;Ladislav Šenolt.;Katalin Fazekas.;Ruben Burgos-Vargas.;Jose Maldonado-Cocco.;Esperanza Naredo.;Philippe Carron.;Anne-Marie Duggan.;Punit Goyanka.;Maarten Boers.;Corine Gaillez.
来源: Rheumatology (Oxford). 2022年61卷5期1867-1876页
To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound.
154. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial.
作者: Yoshikazu Nakaoka.;Masahiro Yanagawa.;Akinori Hata.;Katsuhisa Yamashita.;Norihiro Okada.;Shinji Yamakido.;Hiromitsu Hayashi.;David Jayne.
来源: Rheumatology (Oxford). 2022年61卷6期2360-2368页
Tocilizumab, an anti-IL-6 receptor antibody, was investigated in patients with refractory Takayasu arteritis (TAK) in a phase 3 randomized controlled trial. In this post hoc analysis, we investigated whether tocilizumab treatment inhibited the progression of vascular lesions caused by TAK in these patients.
155. SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study.
作者: Jing Li.;Mengtao Li.;Di Wu.;Jiaxin Zhou.;Shui-On Leung.;Fengchun Zhang.
来源: Rheumatology (Oxford). 2022年61卷5期1841-1848页
SM03, a novel chimaeric mAb specific to B cell-restricted antigen CD22, has been developed to treat RA and other B-cell-related diseases. This 24-week phase II randomized, double-blind, multi-dose, placebo-controlled study aimed to evaluate the efficacy and safety of SM03 in moderately-to-severely active RA patients in China.
156. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
作者: Victoria P Werth.;Roy Fleischmann.;Michael Robern.;Zahi Touma.;Iyabode Tiamiyu.;Oksana Gurtovaya.;Alena Pechonkina.;Afsaneh Mozaffarian.;Bryan Downie.;Franziska Matzkies.;Daniel Wallace.
来源: Rheumatology (Oxford). 2022年61卷6期2413-2423页
To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE).
157. Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
作者: Walter P Maksymowych.;Mikkel Østergaard.;Robert Landewé.;William Barchuk.;Ke Liu.;Chantal Tasset.;Leen Gilles.;Thijs Hendrikx.;Robin Besuyen.;Xenofon Baraliakos.
来源: Rheumatology (Oxford). 2022年61卷5期2063-2071页
To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial.
158. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis.
作者: Aurélie Daumas.;Jérémy Magalon.;Elisabeth Jouve.;Dominique Casanova.;Cécile Philandrianos.;Maxime Abellan Lopez.;Stéphanie Mallet.;Julie Veran.;Isabelle Auquit-Auckbur.;Dominique Farge.;Hervé Levesque.;Ygal Benhamou.;Laurent Arnaud.;Laurent Giraudo.;Chloé Dumoulin.;Camille Giverne.;Olivier Boyer.;Alexandra Giuliani.;Véronique Bourgarel.;Jean-Robert Harlé.;Nicolas Schleinitz.;Julie Brunet.;Yves-Marie Pers.;Rosanna Ferreira.;Audrey Cras.;David Boccara.;Jérome Larghero.;Joseph Château.;Arnaud Hot.;Françoise Dignat-George.;Guy Magalon.;Florence Sabatier.;Brigitte Granel.
来源: Rheumatology (Oxford). 2022年61卷5期1936-1947页
To assess the superiority of adipose tissue-derived stromal vascular fraction (AD-SVF) injection into the fingers vs placebo in reducing hand disability in systemic sclerosis (SSc) patients.
159. Real-time vs static scoring in musculoskeletal ultrasonography in patients with inflammatory hand osteoarthritis.
作者: Lotte A van de Stadt.;Féline P B Kroon.;Frits R Rosendaal.;Desirée van der Heijde.;Monique Reijnierse.;Naghmeh Riyazi.;Ragnhild de Slegte.;Jendé van Zeben.;Cornelia F Allaart.;Margreet Kloppenburg.;Marion C Kortekaas.
来源: Rheumatology (Oxford). 2022年61卷SI期SI65-SI72页
Agreement between real-time and static ultrasonography has not been studied in musculoskeletal diseases. We studied this agreement in inflammatory hand OA.
160. A predictive clinical-radiomics nomogram for diagnosing of axial spondyloarthritis using MRI and clinical risk factors.
作者: Lusi Ye.;Shouliang Miao.;Qinqin Xiao.;Yuncai Liu.;Hongyan Tang.;Bingyu Li.;Jinjin Liu.;Dan Chen.
来源: Rheumatology (Oxford). 2022年61卷4期1440-1447页
Construct and validate a nomogram model integrating the radiomics features and the clinical risk factors to differentiating axial spondyloarthritis (axSpA) in low back pain patients undergone sacroiliac joint (SIJ)-MRI.
|